Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer

BACKGROUND: We conducted the first trial of neoadjuvant PD-1 blockade in resectable non-small cell lung cancer (NSCLC), finding nivolumab monotherapy to be safe and feasible with an encouraging rate of pathologic response. Building on these results, and promising data for nivolumab plus ipilimumab (...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Reuss, Joshua E, Anagnostou, Valsamo, Cottrell, Tricia R, Smith, Kellie N, Verde, Franco, Zahurak, Marianna, Lanis, Mara, Murray, Joseph C, Chan, Hok Yee, McCarthy, Caroline, Wang, Daphne, White, James R, Yang, Stephen, Battafarano, Richard, Broderick, Stephen, Bush, Errol, Brock, Malcolm, Ha, Jinny, Jones, David, Merghoub, Taha, Taube, Janis, Velculescu, Victor E, Rosner, Gary, Illei, Peter, Pardoll, Drew M, Topalian, Suzanne, Naidoo, Jarushka, Levy, Ben, Hellmann, Matthew D, Brahmer, Julie R, Chaft, Jamie E, Forde, Patrick M
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2020
Matèries:
Short Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7488786/
https://ncbi.nlm.nih.gov/pubmed/32929052
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001282
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars